News

Tirzepatide for Teen Obesity: What the New Trial Found

A new trial found that tirzepatide reduced BMI in teenagers with obesity. What the results, side effects and current approvals mean for families.

Teenagers taking tirzepatide in a new clinical trial had a larger drop in body mass index (BMI) than those taking a placebo. The trial gives researchers direct evidence in young people rather than asking them to assume that adult results will apply. It also found that some teenagers stopped the medicine because of side effects. The results are not a new approval for treating obesity in teenagers.

The study, called SURMOUNT-ADOLESCENTS, was published in JAMA on 15 November 2026. It followed 160 teenagers aged 12 to 17 for 72 weeks. They had obesity, or overweight alongside at least one related health complication. This was not a study of teenagers of all weights, and it was not designed to settle how best to treat type 2 diabetes in teenagers.

What did the trial compare?

Researchers assigned participants at random to a weekly injection of tirzepatide or a placebo injection, with about twice as many assigned to tirzepatide. Neither the teenagers nor the people assessing the results knew which treatment each participant received during the blinded period. Both groups also received healthy lifestyle support. The study therefore tested adding tirzepatide to that support, not taking a medicine instead of it.

The trial ran at 31 centres in six countries: Canada, the Czech Republic, Israel, Italy, Poland and the United States. This makes it more informative than a study at one clinic, but 160 participants is still a small group for answering safety questions or comparing results across different backgrounds.

What changed after 72 weeks?

Average BMI fell by 18.5% in the tirzepatide group and rose by 0.5% in the placebo group. The estimated difference was 19 percentage points in favour of tirzepatide, with a 95% confidence interval of 14.1 to 23.9 percentage points in its favour. These figures describe the change in BMI from the starting value. They do not mean that every participant lost 18.5% of their body weight or that their BMI fell by 18.5 points.

BMI is a number calculated from height and weight. During adolescence both can change, and age and sex matter when interpreting the result. The trial used BMI to compare the groups, but a family and care team would also want to consider how a young person is growing, how they feel and whether a treatment is manageable in daily life. A change in one number cannot answer all of those questions.

What about side effects?

Digestive problems, including nausea, vomiting and diarrhoea, were reported by about 82% of those given tirzepatide and 55% of those given placebo. Most were mild or moderate. Ten of the 108 participants who received tirzepatide stopped study treatment because of an adverse event, compared with none of the 51 who received placebo. The safety analysis counts people who received at least one dose, which is why these groups add up to 159 rather than 160.

Eight participants in the tirzepatide group and two in the placebo group had a serious adverse event. The groups were different sizes, and the numbers are too small to say how much the medicine changed the chance of a serious event. Investigators considered some serious events related to assigned treatment, including digestive problems with dehydration and gallbladder events. No deaths occurred during the reported treatment period. That does not establish that rare harms cannot occur.

The researchers also recorded reports of depression or suicidal thoughts in five participants receiving tirzepatide and one receiving placebo. None met the trial’s definition of a serious adverse event. That classification does not make the symptoms unimportant, and the small numbers cannot establish whether the medicine contributed to them.

What the study still cannot tell families

The results cover about a year and a half of treatment. They do not show whether the effects persist years later, what happens in the longer term after stopping, or whether the same results apply to younger children. Only one participant had type 2 diabetes and only one had overweight rather than obesity. The researchers also noted limited racial and ethnic diversity and that many participants had already finished puberty when they joined. The trial compared tirzepatide with placebo, not with another medicine. Eli Lilly, the maker of tirzepatide, funded the study.

Is tirzepatide approved for obesity in teenagers?

As of 16 November 2026, the US prescribing information for Zepbound and the UK and EU product information for Mounjaro list weight management in adults, not adolescents. Some young people aged 10 or older can already be prescribed Mounjaro for type 2 diabetes under those labels. That approval concerns blood sugar in type 2 diabetes. It does not make the medicine approved for adolescent weight management. For the distinction, see our guide to tirzepatide in type 2 diabetes.

What might families ask at an appointment?

If a young person or their family wants to discuss weight and health, useful questions include: What health outcomes matter most for them? What support is available now? How would the team monitor benefits, side effects and growth? The trial does not mean anyone should start, stop, share or change a medicine without speaking to their healthcare team.

Sources

Spread the love